Comparing adverse effects of Hepatitis C drugs using FAERS data
暂无分享,去创建一个
Jingcheng Du | Cui Tao | Rui Duan | Xinyuan Zhang | Jing Huang | Jason H. Moore | Liu Yang | Yong Chen | Jiayi Tong | R. Duan | Jing Huang | Cui Tao | Jingcheng Du | Jiayi Tong | Y. Chen | Liu Yang | J. Moore | Xinyuan Zhang
[1] H. Wedemeyer,et al. Treating viral hepatitis C: efficacy, side effects, and complications , 2006, Gut.
[2] T. Alshammari,et al. Drug safety: The concept, inception and its importance in patients’ health , 2014, Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society.
[3] Yasushi Okuno,et al. Antipsychotics-Associated Serious Adverse Events in Children: An Analysis of the FAERS Database , 2015, International journal of medical sciences.
[4] Viraj Suvarna,et al. Phase IV of Drug Development , 2010, Perspectives in clinical research.
[5] Sammy Saab,et al. Management of Hepatitis C Antiviral Therapy Adverse Effects , 2010, Current hepatitis reports.
[6] Yoon K Loke,et al. Drug safety assessment in clinical trials: methodological challenges and opportunities , 2012, Trials.
[7] Nicholas Moore,et al. Differences between clinical trials and postmarketing use. , 2003, British journal of clinical pharmacology.
[8] Yaoyun Zhang,et al. CD-REST: a system for extracting chemical-induced disease relation in literature , 2016, Database J. Biol. Databases Curation.
[9] Lauren McCormack,et al. Consumer Understanding, Preferences, and Responses to Different Versions of Drug Safety Messages in the United States: A Randomized Controlled Trial , 2015, Drug Safety.
[10] Juan M Banda,et al. A curated and standardized adverse drug event resource to accelerate drug safety research , 2016, Scientific Data.
[11] M. Fried,et al. Side effects of therapy of hepatitis C and their management , 2002, Hepatology.